Skip to Content

Bexsero FDA Approval History

FDA Approved: Yes (First approved January 23, 2015)
Brand name: Bexsero
Generic name: meningococcal group B vaccine
Dosage form: Injection
Company: Novartis Pharmaceuticals Corporation
Treatment for: Meningitis, Meningococcal

Bexsero (meningococcal group B vaccine) is a vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B.

Development Timeline for Bexsero

Jan 23, 2015Approval FDA Approves Bexsero Vaccine to Prevent Serogroup B Meningococcal Disease

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.